{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"7.8","upperLimit":"55.1","value":"26.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Assessed according to RECIST. This is includes complete and partial responses as well as stable disease, and is different from Outcome Measure 6 above, which includes only complete and partial responses.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive temsirolimus IV over 30-60 minutes and cetuximab IV over 1-2 hours once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (Cetuximab and Temsirolimus)"},{"description":"Patients receive temsirolimus as in Arm A. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over to Arm A.","id":"OG001","title":"Arm B (Temsirolimus)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percentage of Responses/Disease Stabilization for Patients Crossing Over to the Combination Therapy After Progressing on Arm B.","type":"SECONDARY","unitOfMeasure":"percentage of participants"}